Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/IIa randomized double-blind placebo-controlled dose-escalation study of oral ecnoglutide tablets in Chinese adults with overweight or obesity
CTR20254195Phase 2Active
- Sponsor
- Sciwind Biosciences
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of ecnoglutide in obesity, Overweight, sponsored by Sciwind Biosciences. Started Nov 2025; status: active.
02
Drugs
ecnoglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20254195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254195.